Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis.
Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis.
复制标题
沙利度胺用于治疗顽固性口腔克罗恩病和口面部肉芽肿病。
DOI：
10.1067/moe.2002.113
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
S. Porter
中科院分区：
文献类型：
--
作者：
A. Hegarty;T. Hodgson;S. Porter
已有研究表明，沙利度胺对克罗恩病的治疗可能是有效的，包括相关的口腔病变。我们详细介绍了5名口腔面部肉芽肿或口腔克罗恩病患者对小剂量沙利度胺的临床反应，这些患者对公认的免疫抑制药物治疗无效。所有患者的症状和体征都得到了临床缓解。短暂性嗜睡是唯一报道的不良反应。通过延长沙利度胺两次给药之间的时间间隔来维持缓解。在接受适当咨询的患者中，沙利度胺应被认为是短期治疗严重口腔面部肉芽肿的有效方法。
It has been suggested that thalidomide may be effective in the management of Crohn's disease, including the associated oral lesions. We detail the clinical response to low-dose thalidomide of 5 patients with clinical features of orofacial granulomatosis or oral Crohn's disease recalcitrant to recognized immunosuppressant therapy. All patients had clinical resolution of their symptoms and signs. Transient somnolence was the only reported adverse effect. Remission was maintained by extending the period between thalidomide doses. Thalidomide should be considered an effective therapy for the short-term treatment of severe orofacial granulomatosis in appropriately counseled patients.
影响因子：
29.4
作者：
Vasiliauskas, EA;Kam, LY;Targan, SR
通讯作者：
Targan, SR